Shares of Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$0.53 and traded as high as C$0.55. Aptose Biosciences shares last traded at C$0.55, with a volume of 9,000 shares traded.
Aptose Biosciences Trading Down 5.5 %
The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.80. The company has a market capitalization of C$9.42 million, a price-to-earnings ratio of -0.09 and a beta of 1.36. The business’s 50 day moving average price is C$0.53 and its two-hundred day moving average price is C$1.01.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported C($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.80) by C$0.21. Equities analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- Options Trading – Understanding Strike Price
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.